Canaccord Genuity Reiterates Buy on Biodesix, Maintains $3.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Kyle Mikson reiterated a Buy rating on Biodesix (NASDAQ:BDSX) and maintained a $3.5 price target.

March 04, 2024 | 3:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst Kyle Mikson reiterated a Buy rating on Biodesix and maintained a $3.5 price target.
The reiteration of a Buy rating and maintenance of a $3.5 price target by a reputable analyst like Kyle Mikson from Canaccord Genuity is likely to instill confidence among investors and could positively influence Biodesix's stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100